MabVax Therapeutics sublicenses therapeutics for patented neuroblastoma vaccine
US clinical-stage oncology drug developer MabVax Therapeutics has granted to Denmark-based Y-mAbs Therapeutics…
Related Articles
- BRIEF—Cellectar gets Rare Pediatric Disease designation for CLR 131 also written by The Pharma Letter
- Anti-tumor activity of safranal against neuroblastoma cells. also categorized in Drug
- Nanoparticles used to enhance chemotherapy also categorized in Drug
- Betablockers repurposed to treat neuroblastoma also categorized in Drug
- GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. also categorized in Drug
- Cancer-killing virus therapy may be improved by low dose of targeted drug also categorized in Drug
- Emend Shows Potential in Pediatric Chemotherapy-Induced Nausea, Vomiting also categorized in Drug
- Research group urges EMA to mandate pediatric cancer trials also written by The Pharma Letter
- Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT. also categorized in Drug
- Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines. also categorized in Drug